Molecular profiles and genomic therapy in young vs. average-onset gastrointestinal (GI) cancers: A Czech national precision medicine network study, GENESIS

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F25%3A00143318" target="_blank" >RIV/00216224:14110/25:00143318 - isvavai.cz</a>
Result on the web
<a href="https://www.sciencedirect.com/journal/annals-of-oncology/vol/36/suppl/S2?page=9" target="_blank" >https://www.sciencedirect.com/journal/annals-of-oncology/vol/36/suppl/S2?page=9</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Molecular profiles and genomic therapy in young vs. average-onset gastrointestinal (GI) cancers: A Czech national precision medicine network study, GENESIS
Original language description
Background Young adults (YA) with GI cancers represent a biologically distinct subgroup. This study examined differences in genomic profiles and indications for genomically driven therapy (GDT) between YA and average-onset (AO) patients across GI cancer types. Methods Data from 625 advanced GI cancer patients enrolled in the Czech national precision medicine platform GENESIS were analyzed. Patients were stratified as YA if aged 20–49 years(y), or AO (≥50 y). A molecular tumor board made GDT recommendations based on NGS comprehensive genomic profiling. Genomic alterations (GA), clinically relevant variants (CRV), and GDT implementation were compared.
Czech name
—
Czech description
—

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)